Tyrosinemia type I
Tyrosinemia type I is a rare genetic disorder characterized by disruptions in the metabolic pathway of the amino acid tyrosine. This condition is the most severe form of tyrosinemia and is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), which is necessary for the final step in the breakdown of tyrosine.
Symptoms[edit | edit source]
The symptoms of Tyrosinemia type I usually become apparent in the first few months of life. They may include failure to gain weight and grow at the expected rate (failure to thrive), diarrhea, vomiting, yellowing of the skin and whites of the eyes (jaundice), cabbage-like odor, and increased tendency to bleed (particularly nosebleeds). Neurological crises characterized by changes in mental state, reduced sensation in the arms and legs (peripheral neuropathy), abdominal pain, respiratory failure, and high blood pressure may also occur.
Causes[edit | edit source]
Tyrosinemia type I is caused by mutations in the FAH gene. This gene provides instructions for making an enzyme called fumarylacetoacetate hydrolase, which is involved in the final step of breaking down the amino acid tyrosine. Mutations in the FAH gene disrupt the function of the enzyme, preventing the body from breaking down tyrosine properly. This leads to a buildup of tyrosine and its byproducts in the body, which can cause damage to the liver, kidneys, and nervous system.
Diagnosis[edit | edit source]
Diagnosis of Tyrosinemia type I is based on the symptoms, laboratory testing showing elevated tyrosine levels in the blood and urine, and confirmed by genetic testing.
Treatment[edit | edit source]
Treatment for Tyrosinemia type I involves a diet low in tyrosine and phenylalanine, medications to reduce the production and absorption of tyrosine, and liver transplantation in severe cases.
Prognosis[edit | edit source]
The prognosis for individuals with Tyrosinemia type I varies. With early diagnosis and appropriate treatment, individuals with this condition can lead a relatively normal life. However, without treatment, severe complications such as liver and kidney failure can occur.
See also[edit | edit source]
References[edit | edit source]
Tyrosinemia type I Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD